Evolus Reaffirms 2026 Revenue Outlook, Cuts Expense Guidance

Evolus retained its 2026 revenue range of $330 million to $337 million and lowered its non-GAAP operating expense outlook to $210 million to $213 million. The company also set a 2028 revenue target of $450 million to $500 million.

The company maintained its 2026 adjusted gross margin outlook at 67% to 67.5%. Its adjusted EBITDA margin outlook remains in the low- to mid-single digits.

CEO David Moatazedi said Evolus had posted positive adjusted EBITDA for four straight quarters and continued to grow above the market. He also pointed to plans for three additional product introductions over the next four years.

Evolysse Sculpt is expected to launch before Lips. The company’s 2028 revenue target is $450 million to $500 million.